Disclosure of Genetic Risk Factors for Alzheimer’s Disease to Cognitively Healthy Individuals—From Current Practice towards a Personalised Medicine Scenario
Authors:
- Samantha GalluzziSGSamantha Galluzzi
- Michela PievaniMPMichela Pievani
- Orazio ZanettiOZOrazio Zanetti
- Luisa BenussiLBLuisa Benussi
- The Italian-DIAfN Working GroupTGThe Italian-DIAfN Working Group
- Giovanni B. FrisoniGFGiovanni B. Frisoni
- Emilio Di MariaEMEmilio Di Maria
Open Access
- 8 December 2022
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3177
Abstract
Alzheimer’s disease (AD) is a genetically complex disorder. In addition to the relatively small number of pathogenic variants causing autosomal dominant AD, many others have been associated with the much more common sporadic form. The E4 allele of the Apolipoprotein E (APOE) is the first discovered genetic risk factor for AD. In addition, more than 70 genetic risk loci contributing to AD have been identified. Current guidelines do not recommend AD susceptibility genetic testing in cognitively healthy adults because the implications for clinical care are limited. However, secondary prevention clinical trials of disease-modifying therapies enrol individuals based on genetic criteria, and participants are often informed of APOE testing results. Moreover, the availability of direct-to-consumer genetic testing allows individuals to learn their own AD genetic risk profile without medical supervision. A number of research protocols for AD susceptibility genetic testing have been proposed. In Italy, disclosure processes and protocols beyond those developed for inherited dementia have not been established yet. We reviewed the literature on the current practice and clinical issues related to disclosing AD genetic risk to cognitively healthy individuals and provide suggestions that may help to develop specific guidelines at the national level.Keywords
Funding Information
- Italian Ministry of Health (GR-2018-12368250)
This publication has 75 references indexed in Scilit:
- Dealing with the unexpected: consumer responses to direct-accessBRCAmutation testingPeerJ, 2013
- Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic CounselorsGenetics in Medicine, 2011
- Informed choice in direct-to-consumer genetic testing for Alzheimer and other diseases: lessons from two casesNew Genetics and Society, 2011
- Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease RiskNew England Journal of Medicine, 2011
- What Is Value in Health Care?New England Journal of Medicine, 2010
- Statement of the ESHG on direct-to-consumer genetic testing for health-related purposesEuropean Journal of Human Genetics, 2010
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseNew England Journal of Medicine, 2009
- A Critical Appraisal of the Scientific Basis of Commercial Genomic Profiles Used to Assess Health Risks and Personalize Health InterventionsThe American Journal of Human Genetics, 2008
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993